Prostatype Genomics AB (publ) reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was SEK 3.79 million compared to SEK 0.683 million a year ago. Net loss was SEK 41.44 million compared to SEK 29.09 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0364 SEK | -3.70% | -17.65% | -61.68% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-61.68% | 3.29M | |
-16.83% | 8.25B | |
+39.20% | 3.58B | |
-39.11% | 2.46B | |
-8.06% | 2.46B | |
-6.54% | 2.38B | |
-19.01% | 1.55B | |
-40.66% | 1.21B | |
+7.56% | 1.11B | |
-14.42% | 1.03B |
- Stock Market
- Equities
- PROGEN Stock
- News Prostatype Genomics AB
- Prostatype Genomics AB Reports Earnings Results for the Full Year Ended December 31, 2023